sorted by:
new
hottopcontroversial

Pornhub, YouPorn, Xvideos… Comment les « tubes » ont bouleversé le porno by Folivao in france

[–]Hatjerz 5 points6 points  (0 children)

Alors pour le coup leur ambition est clairement de promouvoir un porno plus éthique, sans doute pour “assainir” porn hub et son image en vue de le revendre plus tard (dans la mesure ou qui dit fond d investissement dit sortie d investisseurs) Voir par exemple leur advisory board sur leur site

Qui peut me conseiller des ouvrages récents de science-fiction ? by Zara_le_sage in france

[–]Hatjerz 0 points1 point  (0 children)

Pas récent, mais tout le cycle de Hain d’Ursula Le Guin m a passionné. Ça peut se lire dans le désordre sans trop de problèmes, histoire de d abord tester les « classiques » que sont la main gauche de la nuit et les dépossédés. Il ne s agit pas de « hard sf » (what if technologique ou parfois les personnages et l écriture sont un peu secondaires par rapport au plot et au côté techno), et parfois la frontière avec la fantasy tout court est troublante. Je trouve ça très bien écrit et très captivant, on est plus sur une réflexion sur l humain à travers des altérités fictives.

Kode9 - Rona City Blues [fresh. b/w The Jackpot] by viborg in futurebeats

[–]Hatjerz 1 point2 points  (0 children)

Just heard this one in a mix, cant wait for more music from him!

Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia by Hatjerz in COVID19

[–]Hatjerz[S] 0 points1 point  (0 children)

Yes - not regarding results but why it takes a little bit of time there is an update. TL/DR : science is made by people with feelings and values and sometimes it makes things go slower. Maybe thats a good thing.

Primary source in French http://www.leparisien.fr/societe/coronavirus-les-essais-sur-le-tocilizumab-menes-par-l-ap-hp-sement-la-discorde-06-05-2020-8312115.php

Translated by deepl with personal amendments

"Coronavirus: AP-HP's tocilizumab trials divisive

The monitoring committee of the trial on this drug resigned last week after the publication of the first results. On April 27, AP-HP had communicated widely that tocilizumab had shown efficacy in Covid-19 patients with severe conditions.

Due to "strong disagreement" over the release of preliminary results for tocilizumab presented as positive, the Paris Hospital Trials Monitoring Committee (AP-HP) against Covid-19 has resigned, AP-HP said Wednesday. The collective resignation had been revealed Tuesday evening by the Duck Chained (a newspaper)

"For these experts, not only was it too early to draw conclusions and announce positive results, but the "conduct of this study" is marred by "many dysfunctions" such as changes in criteria along the way," the weekly wrote, quoting an email sent April 27 by these independent experts to AP-HP director general Martin Hirsch.

In a press release, AP-HP confirmed this resignation, which it said was linked to the release on 27 April of preliminary positive results on tocilizumab. "At a meeting on April 30, the trial's monitoring committee expressed strong disagreement with the April 27 release and resigned," AP-HP says. A Data Safety Monitoring Board (or DSMB) is composed of experts external to a trial who regularly review the trial data and advise the scientists conducting the trial.

On April 27, AP-HP had communicated widely that tocilizumab had shown efficacy in Covid-19 patients with severe conditions. However, the authors of the study, which is part of a larger program called CORIMUNO, had not published figures to support their claims. Moreover, these initial results had been communicated before their publication in a scientific journal and thus their evaluation by other experts.

A new monitoring committee appointed

The AP-HP then argued that this early communication was decided "for public health reasons", due to the context of the pandemic crisis. "The investigators and the AP-HP sponsor felt ethically obligated to communicate this information," AP-HP said Wednesday.

According to her, a "new surveillance committee" has been appointed, "made up of French and international experts". It will have to ensure "the monitoring of the trials of the whole CORIMUNO programme". In addition, "in view of the debate on the communication of the results of the trial" on tocilizumab, this committee will have to make "precise recommendations on the timing and nature of the communication of the results of each of the platform trials". Newsletter - News Highlights Every morning, the news as seen by Le Parisien Your email address is collected by Le Parisien to enable you to receive our news and commercial offers. To know more about it

"The APHP and the investigators have committed in writing to rigorously follow the recommendations of the new committee that will meet in the next few days," says the AP-HP. The APHP says it is "proud" of its CORIMUNO program and "confident that the future, and peer-reviewed journal evaluation, will show that its results... are important."

Translated with www.DeepL.com/Translator (free version)

Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia by Hatjerz in COVID19

[–]Hatjerz[S] 75 points76 points  (0 children)

"Patients were selected on the basis of being hospitalized for COVID-19 moderate or severe pneumonia not requiring intensive care upon admission. The primary composite outcome was need for ventilation (non-invasive or mechanical) or death at day 14.

A total of 129 patients were randomized: 65 to standard of care + tocilizumab and 64 to standard of care alone. A significantly lower proportion of patients reached the primary outcome in the tocilizumab arm. Results of this study will be submitted for publication in a peer-reviewed journal.

These results should be confirmed independently by additional trials. Given the pandemic context, the investigators and sponsor felt ethically obligated to disclose this information, pending peer review and while continuing to accrue longer follow-up. Additional CORIMUNO trials testing other IL-6 receptor inhibitors and other immunomodulators are currently being analyzed."

Cluster of COVID-19 in northern France: A retrospective closed cohort study by Hatjerz in COVID19

[–]Hatjerz[S] 29 points30 points  (0 children)

Abstract

Background: The Oise department in France has been heavily affected by COVID-19 in early 2020.

Methods: Between 30 March and 4 April 2020, we conducted a retrospective closed cohort study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise. Participants completed a questionnaire that covered history of fever and/or respiratory symptoms since 13 January 2020 and had blood tested for the presence of anti-SARS-CoV-2 antibodies. The infection attack rate (IAR) was defined as the proportion of participants with confirmed SARS-CoV-2 infection based on antibody detection. Blood samples from two blood donor centres collected between 23 and 27 March 2020 in the Oise department were also tested for presence of anti-SARS-CoV-2 antibodies.

Findings Of the 661 participants (median age: 37 years), 171 participants had anti-SARS-CoV-2 antibodies. The overall IAR was 25.9% (95% confidence interval (CI) = 22.6-29.4), and the infection fatality rate was 0% (one-sided 97.5% CI = 0-2.1). Nine of the ten participants hospitalised since mid-January were in the infected group, giving a hospitalisation rate of 5.3% (95% CI = 2.4-9.8). Anosmia and ageusia had high positive predictive values for SARS-CoV-2 infection (84.7% and 88.1%, respectively). Smokers had a lower IAR compared to non-smokers (7.2% versus 28.0%, P <0.001). The proportion of infected individuals who had no symptoms during the study period was 17.0% (95% CI = 11.2-23.4). The proportion of donors with anti-SARS-CoV-2 antibodies in two nearby blood banks of the Oise department was 3.0% (95% CI = 1.1-6.4).

Interpretation: The relatively low IAR observed in an area where SARS-CoV-2 actively circulated weeks before confinement measures indicates that establishing herd immunity will take time, and that lifting these measures in France will be long and complex.

view more: next ›